Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

ClinicalTrials.gov ID: NCT05472090

Public ClinicalTrials.gov record NCT05472090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 24, 2026, 6:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, 14-week Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily at Bedtime in Patients With Multisite Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Study identification

NCT ID
NCT05472090
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Enrollment
63 participants

Conditions and interventions

Interventions

  • TNX-102 SL Drug
  • Placebo SL Tablet Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Aug 17, 2022
Primary completion
Jul 11, 2023
Completion
Jul 26, 2023
Last update posted
Nov 25, 2024

2022 – 2023

United States locations

U.S. sites
29
U.S. states
17
U.S. cities
28
Facility City State ZIP Site status
Accel Research-Birmingham Clinical Research Unit Birmingham Alabama 35216
Tonix Clinical Site Oceanside California 92056
Tonix Clinical Site Santa Ana California 92705
Tonix Clinical Site Centennial Colorado 80112
Tonix Clinical Site Aventura Florida 33180
Tonix Clinical Site Fort Myers Florida 33912
Tonix Clinical Site Orlando Florida 32801
Tonix Clinical Site St. Petersburg Florida 33709
Tonix Clinical Site Alpharetta Georgia 30022
Tonix Clinical Site Atlanta Georgia 30329
Tonix Clinical Site Chicago Illinois 60625
Tonix Clinical Site Des Moines Iowa 50265
Tonix Clinical Site Iowa City Iowa 52242
Tonix Clinical Site Prairie Village Kansas 66208
Tonix Clinical Site New Orleans Louisiana 70124
Tonix Clinical Site Prairieville Louisiana 70769
Tonix Clinical Site Boston Massachusetts 02115
Tonix Clinical Site Boston Massachusetts 02131
Tonix Clinical Site Methuen Massachusetts 01844
Tonix Clinical Site Gulfport Mississippi 39503
Tonix Clinical Site Albuquerque New Mexico 87109
Tonix Clinical Site New York New York 10036
Tonix Clinical Site Williamsville New York 14221
Tonix Clinical Site Shelby North Carolina 28150
Tonix Clinical Site Columbus Ohio 43215
Tonix Clinical Site Dayton Ohio 45432
Tonix Clinical Site Tulsa Oklahoma 74133
Tonix Clinical Site Austin Texas 78737
Tonix Clinical Site McKinney Texas 75070

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05472090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 25, 2024 · Synced Jul 24, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05472090 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →